With your own knowledge and the help of the following document:

Document 1 (Title: Clinical Applications of Combined Antimicrobial Agents): Co-trimoxazole represents a widely utilized antimicrobial combination with distinctive pharmacological properties determining its clinical applications and safety considerations. Formulation analysis confirms this agent comprises a fixed combination of sulfamethoxazole and trimethoprim, typically in a 5:1 ratio, creating a synergistic antibacterial effect through sequential inhibition of bacterial folate synthesis. This combination demonstrates particular therapeutic efficacy against Toxoplasma gondii, establishing it as a mainstay treatment for toxoplasmosis across various clinical presentations including cerebral, ocular, and congenital infections. The synergistic mechanism involves sulfamethoxazole inhibition of dihydropteroate synthetase followed by trimethoprim inhibition of dihydrofolate reductase rather than dihydrofolate synthetase, creating a sequential blockade of distinct steps in the folate synthesis pathway. Adverse effect profiles include potentially severe cutaneous reactions ranging from mild rashes to life-threatening conditions including Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell syndrome), particularly in specific risk groups including HIV-infected individuals. Significant drug interactions necessitate careful prescribing considerations, with concurrent methotrexate administration specifically contraindicated due to additive antifolate effects potentially resulting in severe bone marrow suppression and other toxicities. This interaction occurs through both agents affecting folate metabolism through different mechanisms, with trimethoprim inhibiting dihydrofolate reductase activity necessary for methotrexate clearance. The pharmacokinetic profile demonstrates good oral absorption and extensive tissue distribution, including cerebrospinal fluid penetration explaining its utility in central nervous system infections. These characteristics collectively inform appropriate clinical applications, dosing considerations, monitoring requirements, and contraindications for this widely utilized antimicrobial agent across diverse infectious disease scenarios.
Document 2 (Title: Antiepileptic Drug Interactions: Clinical Implications): Phenytoin represents a widely utilized antiepileptic medication with substantial potential for clinically significant drug interactions requiring careful consideration during concurrent medication administration. Hormonal contraceptive efficacy demonstrates particularly concerning interactions with phenytoin therapy, with multiple case reports and pharmacokinetic studies documenting contraceptive failure during concomitant use. This interaction primarily results from phenytoin's cytochrome P450 induction accelerating contraceptive steroid metabolism, potentially reducing hormonal concentrations below therapeutic thresholds. Practitioners regularly observe reduced contraceptive efficacy necessitating alternative contraceptive approaches for female patients requiring phenytoin therapy. Antimicrobial combinations represent another clinically important interaction category, with trimethoprim-sulfamethoxazole co-administration resulting in significant phenytoin metabolism inhibition through competition for cytochrome P450 catalytic sites. This interaction produces potential toxicity through elevated phenytoin concentrations, requiring either dosage adjustment or alternative antimicrobial selection. Notably, certain histamine-2 receptor antagonists including cimetidine similarly inhibit phenytoin metabolism through cytochrome P450 inhibition, potentially precipitating toxicity with manifestations including nystagmus, ataxia, and cognitive impairment when administered concurrently without appropriate dosage modification. Antifungal therapies demonstrate variable interaction potential, with certain azole compounds significantly affecting phenytoin pharmacokinetics while other antifungals including griseofulvin exhibit minimal interaction potential, with limited documented effect on phenytoin concentrations despite theoretical metabolism-based concerns. Beta-lactam antibiotics including ampicillin demonstrate similar pharmacokinetic compatibility, with minimal documented alterations in phenytoin concentrations during co-administration, allowing their concurrent use without specific dosage adjustments. These variable interaction profiles necessitate individualized medication selection based on specific clinical scenarios, potential alternative agents, and monitoring capabilities.
Document 3 (Title: Quantitative Analysis of Enzyme-Substrate Interactions): Enzyme kinetics represents the quantitative study of enzyme-catalyzed reactions, providing essential insights into catalytic mechanisms, metabolic regulation, and pharmacological interventions. The Michaelis-Menten model serves as the foundational framework for understanding enzyme behavior under varying substrate concentrations. This model proposes that enzymes (E) reversibly bind substrates (S) to form enzyme-substrate complexes (ES), which subsequently convert to products (P) and regenerated enzyme. Under steady-state conditions, where ES concentration remains constant, reaction velocity varies hyperbolically with substrate concentration according to the equation: v = (Vmax × [S])/(Km + [S]). Two fundamental parameters characterize this relationship: Vmax represents the maximum reaction velocity achieved at saturating substrate concentrations, while Km, the Michaelis constant, equals the substrate concentration at which reaction velocity reaches half-maximal (½Vmax). The Km value provides insight into enzyme-substrate affinity, with lower values generally indicating higher affinity. However, interpretation requires caution as Km incorporates multiple rate constants and may not directly equate to dissociation constants in complex reaction mechanisms. The ratio of these parameters (Vmax/Km) defines the catalytic efficiency, a critical metric for comparing enzymes or assessing evolutionary optimization. Experimental determination of these parameters typically employs initial velocity measurements across a range of substrate concentrations under standardized conditions of temperature, pH, and ionic strength. Linearization methods, such as Lineweaver-Burk (double-reciprocal) plots, facilitates parameter estimation, with 1/v plotted against 1/[S] yielding a straight line with slope Km/Vmax, y-intercept 1/Vmax, and x-intercept -1/Km. While historically valuable, modern computational methods using non-linear regression provide more accurate parameter estimates by avoiding statistical distortion inherent in linearization. The kinetic behavior of hexokinase, a representative enzyme catalyzing glucose phosphorylation, epitomizes these principles with relatively low Km values for glucose, reflecting its physiological role in initiating glycolysis at normal blood glucose concentrations.

Answer the following list question.
Question: Select the correct statement(s) regarding co-trimoxazole:
Options:
1. Is an association of sulfamethoxazole and trimethoprim
2. Is indicated in the treatment of toxoplasmosis
3. Trimethoprim is an inhibitor of dihydrofolate synthetase
4. Can cause severe skin disorders such as Lyell syndrome
5. Combination with methotrexate is contraindicated

Respond strictly in valid JSON format as shown below:
{"answer": ["1", "3"]} ← if options 1 and 3 are correct
Only output the JSON object. Do not include explanations, labels, markdown, or any other text.